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Highlights  
 Assessment of clinically significant copy number alterations (CNAs) and copy-neutral 
loss-of-heterozygosity (CN-LOH) in myeloid malignancies by chromosomal microarray 
(CMA) can improve diagnostic yield, refine risk-stratification and provide genomic 
information to guide therapy. The Cancer Genomics Consortium (CGC) Working Group 
for Myeloid Neoplasms performed an extensive systematic examination of the peer-
reviewed literature to evaluate the clinical value of CMA testing in the workup of 
myelodysplastic syndrome (MDS), myelodysplastic/myeloproliferative neoplasms 
(MDS/MPN) and myeloproliferative neoplasms (MPN). Based on the evidence, this 
review describes the specific clinical scenarios where CMA can complement the 
information obtained by current standard-of-care testing modalities. An example of a 
testing algorithm illustrating how CMA can be incorporated in selected settings within 
the backbone of the current testing guidelines is provided. In addition, the current review 
provides an exhaustive list of recurrent CNAs and CN-LOH observed in these myeloid 
neoplasms and their clinical significance.   
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List of Acronyms  
aCGH, array-based comparative genomic hybridization 
CN-LOH, copy neutral loss of heterozygosity  
MDS, myelodysplastic syndrome  
MPN, myeloproliferative neoplasm  
CMA, Chromosomal Microarray 
CGAT, chromosome genomic array testing 
RARS-T (Refractory anemia with ring sideroblasts and thrombocytosis  
SNP-A, single-nucleotide polymorphism array 
NCCN, National Comprehensive Cancer Network 
WHO, World Health Organization  
NGS, Next Generation Sequencing 
FISH, Fluorescence In Situ Hybridization 
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Abstract 
Multiple studies have demonstrated the utility of chromosomal microarray (CMA) testing to 
identify clinically significant copy number alterations (CNAs) and copy-neutral loss-of-
heterozygosity (CN-LOH) in myeloid malignancies. However, guidelines for integrating CMA 
as a standard practice for diagnostic evaluation, assessment of prognosis and predicting treatment 
response are still lacking. CMA has not been recommended for clinical work-up of myeloid 
malignancies by the WHO 2016 or the NCCN 2017 guidelines but is a suggested test by the 
European LeukaemiaNet 2013 for the diagnosis of primary myelodysplastic syndrome (MDS).  
The Cancer Genomics Consortium (CGC) Working Group for Myeloid Neoplasms 
systematically reviewed peer-reviewed literature to determine the power of CMA in 1) 
improving diagnostic yield, 2) refining risk stratification, and 3) providing additional genomic 
information to guide therapy. In this manuscript, we summarize the evidence base for the clinical 
utility of array testing in the workup of MDS, myelodysplastic/myeloproliferative neoplasms 
(MDS/MPN) and myeloproliferative neoplasms (MPN). This review provides a list of recurrent 
CNAs and CN-LOH noted in this disease spectrum and describes the clinical significance of the 
aberrations and how they complement gene mutation findings by sequencing. Furthermore, for 
new or suspected diagnosis of MDS or MPN, we present suggestions for integrating genomic 
testing methods (CMA and mutation testing by next generation sequencing) into the current 
standard-of-care clinical laboratory testing (karyotype, FISH, morphology, and flow).  
 
Keywords:  Copy Number Aberrations, Copy Neutral Loss of Heterozygosity, Microarray, 
Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Next-generation Sequencing  
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Introduction 
 
The integration of genetic data into the clinical and pathological assessment of myeloid 
neoplasms underscores the expanding role of genomic changes in the diagnosis, prognosis, 
classification and therapeutic implications of precision medicine. Myeloid neoplasms include 
myelodysplastic syndrome (MDS), myelodysplastic/ myeloproliferative neoplasm (MDS/MPN), 
myeloproliferative neoplasm (MPN) and acute myeloid leukemia (AML). The myelodysplastic 
syndromes (MDS) comprise a very heterogeneous group of clonal myeloid disorders 
characterized by peripheral blood cytopenias, a bone marrow aspirate/biopsy showing dysplasia 
in one or more hematopoietic lineages and/or the presence of characteristic chromosome 
abnormalities [1, 2]. In addition, karyotype is a critical component of the International Prognostic 
Scoring System (IPSS), the gold standard used to predict overall survival and risk of AML 
transformation in primary MDS patients [3]. The recently revised IPSS or IPSS-R refined the 
cytogenetics categories listed in the original IPSS and provided “greater weight” to the 
cytogenetic categories, underscoring the importance of genetic-based testing in the myeloid 
malignancies [4]. However, karyotype analysis only detects chromosome abnormalities in ~ 50% 
of primary MDS patients.  Thus, to further improve the genetic diagnostic and prognostic 
precision in MDS and identify therapeutic targets, molecular genetic assays such as CMAs and 
NGS are needed. MPNs are clonal hematopoietic disorders characterized by proliferation of one 
or more of the myeloid lineages, while MDS/MPNs have features of both MDS and MPN at the 
time of initial presentation [1]. Per current NCCN guidelines for MPN, the diagnosis of MPN is 
based on the 2016 WHO criteria and requires a combination of clinical, laboratory, cytogenetics, 
and molecular testing [1, 5, 6]. For chronic myeloid leukemia (CML), defined by the presence of 
BCR/ABL1 rearrangement, RT-PCR or FISH with or without conventional karyotype are 
recommended for diagnosis. For BCR/ABL1-negative MPNs, in the absence of mutations of 
JAK2, MPL and CALR, chromosomal abnormalities can represent markers of clonality. 
Similarly, diagnosis of certain subcategories of MDS/MPN such as chronic myelomonocytic 
leukemia is facilitated by detection of chromosomal abnormalities, especially in the absence of 
diagnostic morphologic features [1]. 
 
Downloaded for Anonymous User (n/a) at Indiana University - Ruth Lilly Medical Library from ClinicalKey.com by Elsevier on October 16, 2018.
For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved.
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Numerous studies described below have demonstrated the utility of chromosomal microarray 
(CMA) testing to identify copy number alterations (CNAs) and copy neutral loss of 
heterozygosity (CN-LOH) in myeloid malignancies for diagnostic evaluation and assessment of 
prognosis; certain CN-LOH have significant therapeutic implications due to underlying 
mutations that could be potential therapeutic targets or predict treatment response. However, 
CMA, also known as array comparative genome hybridization (aCGH), single nucleotide 
polymorphism array (SNP-A), chromosome genomic array testing (CGAT), DNA microarray 
testing, genomic array or simply referred to as array, is still not a standard of practice across all 
cancer care institutions. Assessment of genomic aberrations by CMA testing has not been 
addressed by the WHO 2016 or the NCCN guidelines for clinical work-up of hematological 
malignancies [1, 7, 8]; European LeukaemiaNet 2013 has suggested the use of CMA testing for 
the diagnosis of primary MDS [9]. However, at this time, there are no specific guidelines 
available for clinical utilization (i.e., when and how to perform CMA analysis).  
 
To evaluate the clinical utility of CMA in hematological malignancies, the Cancer Genomics 
Consortium (CGC) Working Group for Myeloid Neoplasms was formed comprising 
cytogenetics, molecular genetics, and pathology experts under the auspices of the CGC. An 
extensive systematic examination of the peer-reviewed literature was performed to evaluate the 
clinical value of CMA and to identify the recurrent CNAs and CN-LOH in various myeloid 
malignancies.  According to the 2016 WHO classification, diseases reviewed in this manuscript 
include MDS, MDS/MPN, and MPN including CML. For each recurrent CNA (gain or loss) or 
CN-LOH, the clinical significance of the affected gene(s) in various myeloid disorders and their 
corresponding impact on clinical management were assessed.  
 
Here, we present the evidence base for the clinical utility of array testing in myeloid neoplasms 
(MDS, MDS/MPN and MPN), and provide suggestions for clinical utilization and methodology 
considerations.  
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Materials and Methods  
 
Literature search and review  
A literature search was performed for articles on PubMed using a combination of the following 
terminologies: “MDS; MPN; MDS/MPN; chronic myelomonocytic leukemia (CMML) and 
myeloid neoplasms” with “microarray; SNP array; array CGH; loss of heterozygosity/LOH; 
uniparental disomy/UPD; copy number.  A total of 66 peer-reviewed articles were reviewed in-
depth up to 2017. These studies utilized one of the three common microarray platforms, namely, 
Agilent copy number (CN) or CN+SNP arrays, Affymetrix CN+SNP arrays, or Illumina-SNP 
arrays. The following data from each of the articles were collected: type of study, array platform, 
total number of cases in the study, disease type and WHO sub-classification whenever available; 
time point of testing during the disease course, criteria for making the calls (gains/ losses/ CN-
LOH), diagnostic yield, recurrent CNA and CN-LOH findings and their clinical significance 
(diagnostic/ prognostic/ therapeutic targets) and their role in clonal evolution and disease 
transformation from MDS or MPN to AML. The primary literature was also evaluated to identify 
the spectrum of recurrently affected genomic regions and genes, regardless of known clinical 
significance, in MDS, MDS/MPN or MPN as ascertained through chromosomal microarray 
analysis.  Review articles and articles related to primary or secondary AML cases were 
excluded.  
 
Recurrent CNA and CN-LOH detected across the myeloid neoplasms were retrieved. Clinical 
significance was based on the utility for a) diagnosis; b) prognostication; c) predictive marker for 
therapeutics (targeted agents or precision medicine); and/or d) correlation of other clinical-
pathological findings of interest, e.g., morphologic subtypes, flow cytometry immunophenotype, 
association with somatic mutations, microRNAs, etc. Because variable criteria for aberrant CNA 
and CN-LOH calls were used in the literature, we applied the following consistent inclusion 
criteria for the purpose of this review to obtain comparable data across all articles: included 
CNAs generally ≥100 Kb in size and CN-LOH regions of ≥ 10 Mb and telomeric for CN-LOH 
regions that occurred in ≥ 2 patients in a single study unless of known clinical significance or 
proven somatic by paired germline tissue array analysis.  For each recurrent CNA and CN-LOH, 
gene content (if known), disease type and clinical significance were recorded.    
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The level of evidence for clinical significance of CNAs was assigned as follows: Level 1, well 
established: present in current WHO classification (adapted from IPSS [3]/IPSS-R [4]for MDS) 
[1, 2, 4] and/or professional practice guidelines (NCCN for MDS [7] and MPN [5] and 
International MDS/MPN Working Group's recommendations for MDS/MPN [10]); Level 2, 
emerging: defined here as recurrent (≥5 cases) in well-powered studies with expert consensus; 
and Level 3, other recurrent abnormalities present in either ≥5 cases that do not meet levels 1 or 
2 or in  ≥2 cases of deletion that overlaps a myeloid-associated gene with previously described 
loss-of-function mutations.  The level of evidence for clinical significance of CN-LOH was 
assigned as follows: Level 1, well established, present in current WHO classification and/or 
professional practice guidelines; Level 2, emerging, defined here as present in ≥2 cases, 
including a known myeloid gene from NCCN guidelines (22 genes), ≥10 MB, and at least one 
study proved the affected region is not germline; and Level 3, other recurrent abnormalities 
present in ≥2 cases that do not meet levels 1 or 2 and includes at least one known myeloid gene 
from a non-NCCN guidelines source (99 genes) and ≥10 MB [11]. 
 
Results  
The results of this analysis are organized into different sub-headings for the sake of clarity:   
I. Evidence of improved diagnostic yield by CMA in myeloid neoplasms  
a. Detection of CNAs  
b. Detection of CN-LOH  
c. Utility in cases with non-informative karyotype  
II. Summary of the disease-based prognostic and therapeutic implications of CMA 
findings:   
a. Myeloid disorders classified per 2016 WHO classification: MDS, MDS/MPN and 
MPN(CML and BCR/ABL1 negative MPNs)  
b. Myeloid disorders with specific genetic abnormalities:  del(5q), TET2 alterations, 
TP53 mutations, Trisomy 8 and del(20q)  
c. Bone marrow failure syndrome (BMFS) 
d. Precursor myeloid entities: idiopathic cytopenias of undetermined significance 
(ICUS), idiopathic dysplasia of undetermined significance (IDUS), clonal 
Downloaded for Anonymous User (n/a) at Indiana University - Ruth Lilly Medical Library from ClinicalKey.com by Elsevier on October 16, 2018.
For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved.
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
cytopenias of undetermined significance (CCUS) and clonal hematopoiesis of 
indeterminate potential (CHIP)   
III. Important Pre-analytical and Post-analytical considerations for CMA and limitations 
of CMA testing 
a. Peripheral Blood vs. Bone Marrow  
b. Formalin fixed paraffin embedded (FFPE) material 
IV. Limitations of CMA  
 
I. CMA facilitates improved diagnostic yield in myeloid neoplasms 
 
a. Detection of CNAs  
The overall detection rate by CMA in all myeloid neoplasms ranged between 19 and 83%.  In 
patients with normal karyotype, the detection rate ranged between 33% and 62% [12]. In patients 
with both normal karyotype and normal FISH, CMA detection rate was 25% whereas in patients 
with normal FISH, karyotype and NGS studies, the detection rate was 10% (6 of 59) of patients 
in a large study [13]. The higher detection rate of CMA is due to its ability to detect sub-
microscopic CNAs beyond the resolution of karyotype and FISH.  In addition, CNAs detected by 
CMA are potentially targetable by on-label and off-label FDA approved therapies in 46% of 
patients with myeloid malignancies [13]. The results are summarized in Table 1. Recurrent 
CNAs include gain of chromosomes 1p, 8, 9p, 13 and deletions of 4q, 5q, 7q, 11q, 12p, 17p, 20q, 
21q, among others (see Table 2-4 for the complete list).   
 
Overall, CMA identified 54% cryptic/submicroscopic CNAs in myeloid malignancies with 
normal/ non-informative karyotype [14, 15].  Of those with normal karyotype (study sample size 
ranged between 33 patients to over 200), detection rate was 15%-40.1% [16-21].  The median 
sizes of CNAs were 0.3 Mb and 0.625 Mb for deletions and duplications, respectively [17].  Of 
particular importance, TET2 deletion, noted in 5.6% of myeloid malignancies, is cytogenetically 
cryptic in 50% of cases. CMA is helpful to identify TET2 deletions since FISH is not routinely 
performed in clinical labs [22, 23]. The concordance between FISH and CMA for TET2 deletions 
was 100% [24].  
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Focusing only on MDS, we selected studies with unbiased patient cohorts of at least 30 WHO-
defined MDS patients regardless of karyotype and IPSS/IPSS-R risk scores to enable a more 
accurate estimation of CMA abnormality rate. The review revealed 1) an overall detection rate 
ranging between 28% and 83% [12, 14, 16, 21, 25-31]; 2) detection rate ranging between 10%-
80% in patients with normal karyotype [12, 14, 16, 18, 19, 21, 25, 26, 29-32]; 3) additional 
aberrations identified in MDS patients with del(5q) or del(7q) [33, 34];  and 4) a detection rate of 
up to 50% in MDS cases with unsuccessful cytogenetics [31, 35]. 
 
b. Detection of CN-LOH   
One of the most important advantages of CMA is the identification of CN-LOH that cannot be 
detected using any other standard laboratory techniques. CN-LOH is a frequent chromosomal 
lesion in MDS, CMML, and MDS/MPN [36] and could involve almost any chromosome (Table 
2). The overall frequency of CN-LOH in myeloid neoplasms ranged between 6% and 41% 
(Table 1) although the frequency in MDS was much lower than in MDS/MPN [31, 36].  Akagi 
et al reported that 32% of AML/MDS patients with normal karyotype had CN-LOH with a 
median size of 30.91 Mb [17]; Heinrichs et al reported CN-LOH in 15% of MDS patients, with 
all CN-LOH validated as somatic by comparison to buccal cells. The latter study concluded that 
the presence of acquired CN-LOH helped in making the diagnosis of MDS based on 
identification of a clonal genetic abnormality [16]. The presence of 4q24 CN-LOH correlated 
with myeloproliferative features and was mostly noted in MDS/MPN whereas 4q24 
microdeletions were more common in MDS (enriched in MDS with ring sideroblasts and 
multilineage dysplasia sub-category) and secondary AML (sAML) [23, 37]. CN-LOH of 17p 
was noted in 18% of 72 newly diagnosed MDS patients with complex chromosomal alterations, 
all of which had a TP53 mutation [38]. 
 
Identification of CN-LOH is a marker of clonality and pinpoints a possible underlying 
homozygous gene mutation; for example, CN-LOH of 1p, 11q, 9p, 13q and 17p are associated 
with mutations in KIT/NRAS, CBL, JAK2, FLT3  and TP53 genes, respectively; homozygous 
mutations in the latter four genes have been associated with disease progression [23, 36, 39-41]. 
The pathogenic significance can be inferred by the identification of characteristic 
clinicopathological findings associated with specific CN-LOH: advanced MDS/AML in the 
Downloaded for Anonymous User (n/a) at Indiana University - Ruth Lilly Medical Library from ClinicalKey.com by Elsevier on October 16, 2018.
For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved.
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
presence of 17p CN-LOH; mixed MDS/MPN, monocytosis and a high propensity for AML 
transformation in the presence of 11q CN-LOH [36]. Furthermore, homozygous mutations due to 
CN-LOH, such as JAK2 mutations with 9p CN-LOH, FLT3 ITD mutations due to 13q CN-LOH, 
TP53 mutations due to 17p CN-LOH, and CBL mutations due to 11q CN-LOH have been 
associated with disease progression [36, 39-41]. Aside from the mutations, CN-LOH by itself 
can confer poor prognosis, as shown by poor outcome in MDS patients with CN-LOH of 7q, 
similar to MDS with del(7q) [12, 16, 38, 41].  
 
c. Utility in cases with non-informative karyotype (failed or less than 20 metaphases) 
Gondek et al. reported CNAs in up to 44% of myeloid neoplasms with non-informative 
karyotype [12]. Arenillas et al. identified abnormalities in 50% of patients including CN-LOH of 
3q in addition to common abnormalities of 5q, 7, and 8 [35]. The authors identified significant 
differences in overall survival (OS) between IPSS and IPSS-R cytogenetic risk groups that were 
calculated based on the CNA data obtained from SNP arrays [35].  CMA can also help refine the 
nature of ambiguous cytogenetic findings,, such as additional material (add), marker and ring 
chromosomes (mar, ring), double minutes (dmin) which can represent amplification (e.g. 
MLL/KMT2A, MYC) and delineate the breakpoints in chromosomal rearrangements [42].  
 
Summary: Taken together, these data emphasize the considerable diagnostic yield of CMA in 
detecting submicroscopic CNAs and CN-LOH in myeloid neoplasms.  Specifically, because 
CMA recapitulates most of the findings of karyotype studies in normal and non-informative 
(failed or limited growth) cases, it adds diagnostic value. In addition, CN-LOH pinpoints regions 
harboring possible homozygous mutations.  
 
II. Summary of the disease-based prognostic and therapeutic implications of CMA 
findings 
 
Because of the heterogeneous nature of the disease subtypes included in this review, we detail 
the relevant prognostic and therapeutic implications of CMA findings within various disease 
entities based on WHO classification, including MDS, MDS/MPN (CMML and MDS/MPN-U), 
CML, and BCR/ABL1-negative (Ph-negative) MPNs, as shown below.  Bone marrow failure 
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syndrome (BMFS) and precursor MDS are also discussed separately. Table 1 highlights the 
literature review results, and Table 2-4 lists all recurrent CNAs or CN-LOH reported to date.  In 
both tables, we classify the types of recurrent CMA findings based on the level of evidence as 
defined in Methods. 
 
a. Summary of the disease-based prognostic and therapeutic implications of CMA findings in 
myeloid disorders classified per 2016 WHO classification  
 
Myelodysplastic syndrome (MDS) 
Multiple studies have shown that detection of additional aberrations by CMA in patients 
diagnosed with MDS has prognostic value [14, 26, 42, 43]. Tiu et al. showed that the outcome of 
patients with chromosomal defects detected by either karyotype or array was worse than that of 
patients in whom no lesions were detected for OS (16 vs 43 months; P ≤ 0.0001), event-free 
survival (EFS) (12 vs 20 months; P = 0.0006), and progression-free survival (PFS) (11 vs 17 
months; P =0.002) [14]. Regardless of prior karyotype, survival of patients with new defects 
uncovered by array testing was significantly inferior compared to patients with a negative result 
[14]. Multivariable analysis showed that the presence of new array-detected lesions and an 
increased number of such lesions (2 vs 1 or none) were independent predictors of inferior OS and 
EFS in patients with MDS and related myeloid malignancies [14]. Due to higher yield of 
chromosomal abnormalities, Tiu and colleagues suggested that CMA testing facilitates better 
prognostic stratification of MDS using the IPSS scoring system leading to significant impact on 
treatment selection. Within MDS patients with IPSS intermediate-1 risk group, the survival 
curves for patients with and without additional abnormalities by CMA diverged (median survival 
28 versus 9 months, P=0.03) [12]. Within the low-risk IPSS groups, patients with additional 
CMA–detected defects had worse OS although EFS or PFS did not differ; this finding did not 
extend to the high-risk group [14]. Further, total genomic aberrations (TGA) measured by CMA 
can further stratify MDS patients with both low and high IPSS/IPSS-R scores [26, 44].   
 
The prognostic impact of CNAs in MDS with normal karyotype was also confirmed by Thiel et 
al. among 107 patients from the German (Duesseldorf) registry [18]. A total of 43 (40.1%) MDS 
cases revealed both common recurrent (4q, 5q, 7q, 21q) and other individual CNAs. The median 
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survival among the patient group without CNAs was 56 months in comparison to 20 months in 
the group with CNAs (P=0.002) [18].  A few other papers that focused on MDS with normal 
karyotype did not show significant prognostic impact by multivariable analysis, presumably due 
to small sample size [19, 20].  Nevertheless, 20% of low-risk (good or very good) MDS cases 
had a major cryptic CNA [21]; therefore the risk category was modified for more accurate 
stratification of these patients. 
 
A common concern is whether CMA-detected abnormalities convey the same prognostic effect 
of well-defined karyotypic abnormalities. Gondek et al. compared the survival outcome among 
patient groups with 1) normal CMA testing results, 2) previously known deletion 7/7q by 
karyotype, and 3) those with normal karyotype but new cryptic lesions of chromosome 7 
detected by CMA (including 7q deletions and CN-LOH). The patients with new cryptic lesions 
by CMA showed similar outcomes as the patients with previously known deletion 7/7q; as 
expected, their outcome was significantly worse than patients with normal karyotype by 
karyotype and CMA (median survival 6 vs 8 vs 39 months, respectively, P=0.002) [12].  
 
In terms of predictive markers in MDS, the best known is del(5q).  Patients with this abnormality 
respond well to lenalidomide.  As an example, CMA helped to identify cryptic 
del(5)(q31.3q33.2) (12 Mb) in a patient [19] whose WHO diagnostic classification was 
subsequently changed from MDS-RA to 5q- syndrome (included in the commonly deleted 
region); neither karyotype analysis nor MDS FISH probes using the most common 5q- probe 
targeting EGR1 at 5q31 could identify del(5)(q31.3q33.2). However, a FISH probe targeting the 
more distal region of 5q33 was able to confirm the CMA finding [19].  
 
Low-risk vs high-risk MDS (based on IPSS or IPSS-R) 
Identification of cryptic aberrations using CMA analysis can facilitate prognostic stratification in 
lower-risk IPSS patients [45]. 20% of MDS patients with low-risk (good or very good) had a 
major cryptic CNA [21].  Within low-risk MDS (IPSS < 1), Starczynowski et al. showed that the 
presence of aberrations of more than 3Mb was associated with a lower OS and more frequent 
transformation to AML [26].  In a large series of 119 low-risk MDS patients, there was a 
correlation between a higher IPSS score and presence of CNAs. Specifically, deletions were 
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associated with higher IPSS scores compared with amplifications (p=0.007) [45]. Although 
univariate analysis showed that deletions and IPSS scores correlated with OS, only IPSS scores 
retained prognostic significance by multivariate analysis [45]. In low-risk MDS patients with 
normal karyotype, a significantly shorter OS was observed for patients with additional 
aberrations compared to patients without additional aberrations (p=0.017) [18]. Similar findings 
were observed independently in another study where MDS patients with low-risk IPSS with 
additional CMA abnormalities had worse OS (but not EFS or PFS) [14].  
 
In addition, CMA improved patient stratification even in high-risk MDS patients. The detection 
rate of CMA abnormalities was much higher (up to 80% for new aberrations not identified by 
karyotype) in MDS patients with abnormal karyotype [46, 47]. In a study on high-risk MDS 
patients treated with azacitidine, identification of CMA abnormalities greater than 100 Mb 
correlated with worse OS [44]. Within high-risk MDS/AML patients with del(5q) or highly 
complex karyotypes, the amount of genetic rearrangements and fragmentation status had an 
effect on outcome and response to treatment [48]. Specifically, total genomic aberration size 
(<200 Mb) was predictive of improved OS. Within these patients, TP53 mutation was associated 
with therapy refractoriness only if accompanied by heavily rearranged chromosomes [48]. In 
newly diagnosed MDS patients with complex chromosomal aberrations, CN-LOH of 17p (~18% 
of patients) correlated with aggressive clinical course [38].  Thus, CMA analysis has a significant 
prognostication value in both low-risk and high-risk MDS.  
 
Summary: CMA adds prognostic value in MDS patients with normal karyotype and in MDS 
patients with low or intermediate IPSS-R risk, especially when on the interface of an IPSS-R 
range, by providing genomic-based evidence (CNAs or CN-LOH) to either upgrade or 
downgrade risk to optimize patient management.   
 
Myelodysplastic/ Myeloproliferative neoplasms (MDS/MPN)  
Within MDS/MPN, chromosomal aberrations were detected in 75% of patients by CMA as 
opposed to 37% by conventional cytogenetic studies [12]. Recurrent CNAs included gains of 
chromosomes 8 and 21q and losses of 4q, 5q, 7q, 12p, 13q, 17p, and 20q (Table 2).  The overall 
survival of patients with MDS/MPN and sAML with additional lesions by arrays was lower than 
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patients with normal karyotype and array results [12]. When patients with MDS/MPD-U who 
progressed to AML were compared to those with a stable course of the disease, CMA showed, as 
expected, a greater number of lesions detected in the first group; however, no survival difference 
was noted between patients with or without previously cryptic defects, likely due to the small 
sample size [43]. 
 
In addition to cryptic CNAs, CN-LOH is frequently observed in MDS/MPN and often as a 
solitary lesion and may represent clonality [37] (seeTable 3 for details). CN-LOH was more 
frequent in patients without a JAK2 mutation (frequently involved chromosome 11) compared to 
MDS/MPN patients with a JAK2 mutation (frequently involved chromosome 9) [43]. Dunbar et 
al. reported frequent CN-LOH in both CMML (48%) and MDS/MPN-unclassifiable (38%) and 
also in secondary AML arising from MDS/MPN [36]. The authors discovered novel mutations in 
the CBL gene at 11q23.3 in 58% of patients [36] thereby establishing CN-LOH of chromosome 
11q as an important clue to homozygous CBL mutation [36]. Similarly, Jankowska et al. found 
that CN-LOH of chromosome 4q was also frequent in MDS/MPN and in secondary AML arising 
from MDS/MPN including CMML; however, it was absent in RARS-T (Refractory anemia with 
ring sideroblasts and thrombocytosis) or atypical CML. In contrast, microdeletions of 4q24 were 
noted in MDS [23]. CN-LOH of 4q was associated with TET2 mutations in all cases, but TET2 
mutations were less frequent in cases with microdeletions. Morphologically, myeloproliferative 
features were apparent in cases with CN-LOH of 4q and not in deletion of 4q (TET2), suggesting 
that either CN-LOH of 4q or TET2 mutation conferred these features [23].  
 
Summary: MDS/MPN patients could benefit from CMA because of high CN-LOH frequency in 
this disease group, which cannot be otherwise detected, and the additional CMA lesions have 
significant survival impact and are associated with disease progression. 
 
Myeloproliferative Neoplasms (MPN) 
  Chronic myelogenous leukemia (CML)  
CNAs are not infrequent in CML even in chronic phase.  Four studies of unique CML patients 
have been reported with CMA analysis with a total of 259 patients, 214 of which also had a 
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karyotype [15, 49-52].  Overall, CMA identified 121 CNAs in 84 patients and the one study that 
assessed LOH identified 65 LOH regions (>3Mb) in 19 patients [49].   
 
In one large study, CMA detected abnormalities in 21% with the size ranging between 0.1 and 52 
Mb [49]. Submicroscopic deletions at 9q34 and 22q11.2 were seen in 12%, with half occurring 
right at the BCR or ABL1 breakpoint. 1p CN-LOH and 9p CN-LOH (JAK2 mutation positive) 
were seen in one patient each, but are known to be recurrent [49]. Another study also showed a 
detection rate of 24% in chronic phase CML patients; recurrent losses of 9q34 and 22q11.2 were 
noted at t(9;22) breakpoints [15]. 
 
Nowak et al. explored the genomic alterations in tyrosine kinase inhibitor (TKI) resistant CML 
patients. In addition to t(9;22), 26 of 45 (57.8%) patients had an abnormal CMA result. On 
average, there were 1.68 CNAs per TKI-resistant patient. These included a total of 36 deletions, 
29 duplications, and 9 types of CN-LOH. Recurrent lesions in this cohort included 1p and 19q. 
The common secondary findings at time of TKI resistance were extra BCR/ABL1, trisomy 8 and 
deletion of TP53 [50].   
 
Boultwood et al. explored a gamut of chromosomal alterations during disease progression in 41 
CML patients using array testing. Twelve of the 41 patients in this cohort had paired samples in 
chronic and blast phases. Overall, 75.6% patients showed abnormalities by array, including 
unique findings of 41 CN-LOH and 9 CN gain in 27 patients with available karyotype for 
comparison.  However, most CN-LOH were not convincing because a low-resolution 50K array 
was used and the cut-off was set below 5Mb, unless lesions were noted only during the blast 
phase of the paired-sample analysis.  Recurrent deletions >1 Mb involved chromosomes 12p and 
17p (TP53). Mutation in ASXL1 exon 12 was detected in 15% patients in both chronic and blast 
crisis phase.  Of note, all patients in this cohort were of pre-imatinib era [51].  
 
Summary: Although CMA could identify many additional clonal findings in CML patients, 
especially those at the time of TKI resistance and disease progression, no clear prognostic and 
predictive value of CMA findings has been established to date. 
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  BCR/ABL1-negative MPN    
CMA is able to detect all clonal abnormalities seen in BCR/ABL1-negative MPN by karyotype, 
such as +1q (14%), gain or loss of 6p (7%), +8, and deletions of 12p, 13q and 20q in primary 
myelofibrosis [53, 54]. In addition, frequent additional alterations uniquely detected by CMA 
included 6p CN-LOH (12.5%), 9p gain/CN-LOH (18.8%), and 22q deletion (12.5%) [54]. In 
MPN and MDS/MPN, 9p CN-LOH was the most common, accounting for 41% overall and 
100% in polycythemia vera (PV) [55]. BCR/ABL1-negative MPN with homozygous JAK2 
mutations had frequent 9p CN-LOH while those with heterozygous JAK2 mutations had no 
detectable 9p CN-LOH [43]. Recurrent CN-LOH of 1p associated with MPL mutations in 
essential thrombocythemia (ET) and 11q CN-LOH associated with CBL mutations have been 
reported in myelofibrosis. 
 
The main concern for MPN patients is disease progression, either to myelofibrosis or to acute 
leukemia.  Several studies compared the genomic profiles of stable disease vs. progression 
among MPN patients.  In MPNs, the average number of aberrations increased over the course of 
disease progression (3 vs. 0.6 in patients with and without progression, respectively). When 
excluding 9p CN-LOH, the incidence of genomic changes (both CNA and CN-LOH) was 
significantly higher in patients with disease progression than in patients without disease 
progression (63% and 0%, respectively, p=0.01) [55]. Similarly, Thoennissen et al. reported up 
to 3-fold more genomic changes in MPN at the time of leukemic progression compared to 
chronic phase (p<0.001) [56]. Rumi et al. also demonstrated that disease progression of PV or 
ET to either secondary myelofibrosis or AML was associated with a significant increase in the 
number of chromosomal aberrations, and no change in the mutant allele burden of JAK2 
mutation [39].  This was also true in patient without CN-LOH of 9p [39]. In a series of 408 
samples, Klampfl et al. reported that changes involving 1q and 9p were strongly associated with 
secondary myelofibrosis or progression to accelerated phase whereas, changes involving 
chromosomes 1q, 3q, 5q, 6p, 7p, 7q, 19q, and 22q were associated with post-MPN AML when 
compared to chronic phase MPN [57]. Thoennissen et al. reported trisomy 8 or 8q24 
amplification was almost exclusively detected in JAK2V617F negative patients with MPN blast 
phase [56]. Also, CN-LOH of either 7q or 9p including homozygous JAK2V617F was related to 
decreased survival after leukemic transformation (P=0.01 and P=0.016, respectively) [56]. 
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Among patients with progression, 80% showed a CMA abnormality at baseline. All patients with 
9p CN-LOH as a sole abnormality did not progress, suggesting this was a favorable marker [55] 
even though a higher JAK2 mutant burden (>50%) in PV has been reported to associate with a 
higher risk of developing myelofibrosis [58]. Nevertheless, AML transformation arose in either 
the clone with 9p CN-LOH and homozygous JAK2 mutation or a new JAK2-negative clone with 
normal chromosome 9 [43]. In PV patients, 9p aberrations (either as CN-LOH and/or gain) were 
associated with progression to post-PV MF, and this may result in a higher JAK2 mutant allele 
burden [39]. More importantly, there was a significant association between the acquisition of 
aberrations of chromosome 5, 7, or 17p and progression to blast phase [39]. The presence of one 
or more of these aberrations was independently associated with reduced overall survival from the 
time of diagnosis of MPN (HR 18, 95% CI 1.9–164, P = 0.011) and progression to AML (OR 
5.9, 95% CI 1.2–27.7, P = 0.006) [39].  
 
Puda et al. compared the CNAs between secondary AML or blast transformation of MPN and 
chronic phase of MPN or MDS. Within secondary AML or blast transformation of MPN, the 
detection rate was 83.1%; recurrent CN-LOH, according to descending frequency, included 9p, 
11q, 17p, 1p or 22q, 4q or 19q, and 6p. Deletions of polycomb repressive complex 2 (PRC2) 
members were significantly enriched in secondary AML compared with chronic phase MPN or 
MDS: JARID2 on 6p, AEBP2 on 12p, SUZ12 on 17q, and EZH2 on 7q; in contrast, PRC2 
sequence mutations were rare, thereby suggesting that deletions were the main type of defect of 
PRC2 loci in myeloid malignancies [59].  
 
Summary: CMA testing in the workup of BCR/ABL1-negative MPN has clinical value. The 
detection of increasing number of genomic lesions was associated with disease progression, and 
CN-LOH was common.  Specific changes were associated with the type of progression (1q/9p 
with myelofibrosis and 3q, 5q, 6p, 7p, 7q, 19q, and 22q with post-MPN AML), and acquisition 
of certain abnormalities (5, 7, or 17p) was independently associated with survival. It is helpful 
that 80% of patients with progression showed CMA abnormalities at baseline. Therefore, CMA 
can be helpful to identify patients who are more likely to progress.  
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b. Summary of the disease-based prognostic and therapeutic implications of CMA findings in 
myeloid disorders with specific genetic abnormalities  
 
  Del(5q)  
Monosomy 5 or deletion 5q abnormalities are frequent in myeloid malignancies.  Chromosome 5 
abnormalities were identified in approximately 440 cases in this review series by karyotype 
/FISH (n=390) or CMA (n=440) with a concordance of ~90% between these techniques [12, 14, 
15, 19, 26, 28, 29, 33-35, 39, 43, 46, 48, 60-64]. A total of 14 cases (3.2%) were missed by either 
CMA (n=4) or karyotype/FISH (n=10) and array was able to identify chromosome 5 
abnormalities in 43 (11%) cases in which karyotype analysis failed.  
 
Deletion of 5q as the sole abnormality in primary MDS is associated with a good cytogenetic risk 
in IPSS-R.  From our review, of the 392 abnormal karyotypes, 209 had a 5q abnormality as the 
sole abnormality by karyotype analysis; but not all studies reported on the analysis of regions 
outside of 5q by CMA. For the studies that addressed additional aberrations identified by CMA 
compared to karyotype, 100 cases showed sole 5q abnormalities by karyotype compared to only 
53 cases by CMA. This finding could potentially upgrade the IPSS-R determined using 
conventional karyotype.  One study that assessed these patients for response to lenalidomide 
showed no significant difference in the response of patients with 5q deletions as the sole 
abnormality and those with additional abnormalities detected by CMA [60].   
 
Despite the lack of correlation with treatment response, one study identified significant 
differences in OS between patients with del(5q) as the sole abnormality by karyotype (median 
OS = 34 months) compared to 5q abnormalities (loss and CN-LOH) identified by CMA only (OS 
= 15 months) [14].  Furthermore, using CMA to refine 5q deletion breakpoints, Stengel et al. 
have shown in MDS, MPN and MDS/MPN cases that the size of 5q deletion correlated with the 
number of additional CNAs detected by array, and TP53 mutations were correlated with a larger 
del(5q) size and with disease progression and worse prognosis [62]. 
 
According to the WHO 2016 recommendation, in patients with isolated del(5q), which may 
include one additional abnormality with the exception of del(7q) or monosomy 7, testing for 
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TP53 mutation is recommended to identify an adverse subset of del(5q) syndrome [1]. TP53 
mutations/deletions are markers of clonal progression and predictors associated with a poor 
response to lenalidomide and an increased risk of AML transformation in del(5q) patients [65-
67].  
 
Summary: Almost 50% of cases with del(5q) as the sole abnormality had additional chromosome 
aberrations identified by CMA.  As only one study has addressed the response to treatment, 
further studies are necessary to potentially identify particular chromosomal regions that could 
predict response to therapy. 
 
  TET2 alterations  
TET2 alterations (deletion, CN-LOH, and mutations) are evident in every type of myeloid 
malignancies (Table 2). TET2 deletions are cytogenetically cryptic in 50% of cases, and need 
either FISH or CMA for identification [24]. In a study on 893 adult patients with myeloid 
malignancies, using FISH, TET2 deletion was found in 5.2% AML, 4.8% MDS, 6.9% CMML, 
and 6.3% MPN [24].  By using CMA, the size of the TET2 deletions was variable, ranging 
between 0.6 and 17.2 Mb. While concordance between FISH and CMA is high, CMA has the 
advantage of detecting CN-LOH.  In TET2-deleted patients, TET2 mutations were detected in 
19/37 (51.4%) by NGS, including 10/14 (71.4%) CMML, 6/16 (37.5%) AML, 2/4 (50%) MDS 
and 1/3 (33%) MPN.  JAK2 V617F was detected in 6/18 TET2 deleted patients (33%).  CBL 
mutation was also found in 2/36 (5.5%) patients.  In de novo AML (n=301), TET2 deletion was 
associated with intermediate- and poor-risk cytogenetics; among patients with intermediate-risk 
cytogenetics, TET2 alteration had worse OS and EFS [24].  
 
Importantly, alterations of TET2 could be a potential marker associated with response to 
demethylation agents. Specifically, clonal TET2 mutations (>10% variant allele frequency) were 
associated with improved response to treatment with hypomethylating agents, although there was 
no improvement in overall survival [68-70]. The response was more robust in the absence of 
ASXL1 mutation [68]. Similarly, mutations in TET2 and/or DNMT3A independently predicted 
better response to DNA methyltransferase inhibitors [71].  
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Summary: CMA can help uncover TET2 deletion as it is cytogenetically cryptic in 50% of cases 
and FISH is not routinely performed. TET2 deletion is associated with TET2 mutation, which 
could be a marker of improved response to hypomethylating agents.  
 
  TP53 mutations  
A number of studies have reported deletions, mutations and CN-LOH of the short arm of 
chromosome 17p encompassing the TP53 gene as a recurrent abnormality in MDS (Table 1 and 
2).  TP53 mutations were frequently associated with MDS with del(5q) and complex cytogenetic 
abnormalities [72]. In a study of 106 patients with MDS, MDS/MPN, and MPN associated with 
deletion 5q, using CMA, the size of the deletion ranged between 16 and 119 Mb with a median 
of 70 Mb. In that study, the highest mutation frequency was reported in TP53 (overall frequency 
31%, frequency in MDS was 36%) followed by JAK2 (23%) and DNMT3A (18%). While there 
was no significant differences in size of the deletions between the various WHO defined entities, 
cases with larger deletions (defined as ≥70 Mb) had a significantly higher frequency of TP53 
mutations [62].   In a separate study of 72 newly diagnosed MDS patients with complex 
chromosomal abnormalities, 17p CN-LOH was detected by CMA in 18% of the patients, 
distributed as follows:  38.4% RAEB-2, 46.1% MDS-AML, in 7.6% of RCMD and 7.6% of 
MDS-unclassified.  CMA characterized the average size of the CN-LOH region to 8.2–20.8 Mb 
encompassing the TP53 gene.  All of the 17p CN-LOH patients in this study also had mutations 
of TP53 [38]. Within high-risk MDS/AML patients with del(5q) with and without additional 
cytogenetic abnormalities treated with a sequential combination of azacitidine and lenalidomide, 
TP53 mutations were associated with increased genomic instability, and the total number of 
genomic alterations <200 Mb was predictive of improved OS (p=0.046), while TP53 mutations 
by itself did not predict response to therapy. Further, TP53 mutated patients showed therapy 
refractoriness only when accompanied by heavily rearranged chromosomes, while TP53 mutated 
patients without heavily rearranged chromosomes responded to treatment [48].  
 
Summary: CMA study has shown that cases with 17p CN-LOH were often accompanied by 
homozygous mutations of the TP53 gene. LOH (deletion, mutation, or CN-LOH) at 17p was 
strongly associated with a complex karyotype and deletions of 5q and 7q.  In a newly diagnosed 
MDS patient, this could trigger a rapid clonal evolution with high risk [38]. 
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 Trisomy 8 and del(20q)  
Trisomy 8 and del(20q) are most common among sole cytogenetic abnormalities but are not 
diagnostic of MDS in the absence of morphological dysplasia. In one study, CMA analysis on 
trisomy 8 MDS/AML patients revealed additional submicroscopic CNAs in 40% of cases, 
including a recurrent 12p deletion encompassing the ETV6 locus [73]. A possible association was 
reported between IDH mutations and trisomy 8 [74]. Two or more additional CNAs/CN-LOH 
identified by CMA in these patients would reclassify a patient from intermediate-risk to high-risk 
because of complex karyotype, defined as 3 or more clonal abnormalities [75]. In a study of 306 
MDS patients, the commonly deleted region (CDR) for del(20q) was defined as 4.6 Mb in size 
encompassing 96 genes, flanked by PTPRT at 20q13.11 and EYA2 at 20q13.12 [76]. CMA 
analysis on 30 of these patients showed no significant difference in deletion size in early or 
advanced MDS cases. Additional aberrations equal to or greater than 3 by karyotype were seen 
in 10.2% of patients with significantly worse 2-year OS (0% vs. 87.7%, HR 27.5, p=0.003) by 
multivariate analysis.  Sequence analysis identified mutations in U2AF1 (20%), SRSF2 (19.5%), 
ASXL1 (16.3%), RUNX1 (8.9%), and SF3B1 (5%); only ASXL1 mutation status had a significant 
impact on prognosis (2-year OS of 45.5% vs. 87.9% with and without ASXL1 mutation, 
respectively, p=0.002). ASXL1 mutations typically occurred outside of CDR and were associated 
with advanced MDS [76].   
 
Summary: CMA may identify abnormalities in addition to trisomy 8 or del(20q) in patients with 
MDS or suspected MDS.  Aside from complex karyotype, the prognosis of these additional 
findings is unclear.  Larger studies are necessary to determine if additional abnormalities, 
identified by CMA but not by karyotype, impact prognosis. 
 
c. Summary of the disease-based prognostic and therapeutic implications of CMA findings in 
bone marrow failure syndrome (BMFS) 
 
Revised 4
th
 edition of WHO classification has recognized myeloid neoplasms with germline 
predisposition [1]. CMA testing is especially useful in these settings as cells from patients with 
bone marrow failure syndromes such as aplastic anemia (AA) are typically hard to grow in vitro 
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[77]. CMA can detect additional aberrations in AA patients and hypocellular MDS beyond 
karyotype. Serial longitudinal CMA analyses were able to identify monosomy 7 in four AA 
patients, consistent with progression, earlier than karyotype analysis [77]. CN-LOH of 6p 
involving the HLA locus was a frequent abnormality seen in 11% of AA patients [78, 79]. CN-
LOH of 6p is a mechanism for cells evading the immune system, rather than a malignant process 
and is often associated with multiple clones. None of the AA patients with 6p CN-LOH 
developed MDS or additional MDS-related cytogenetic abnormalities [79]. However, none 
achieved long-term remission with immune suppressive therapy either [79]. An important 
consequence to note is that HLA typing of peripheral blood could give inaccurate or ambiguous 
results if CN-LOH 6p is present.  
 
A comprehensive CMA analysis was performed on 91 patients with various BMFS including AA 
with and without PNH, Fanconi Anemia (FA), Dyskeratosis Congenita, Diamond Blackfan 
Anemia, Shwachman Diamond Syndrome, severe congenital neutropenia and BMFS that could 
not be classified. CMA facilitated identification of a number of pathogenic abnormalities (low-
level acquired CNAs, CN-LOH, and inherited regions of homozygosity) that were not identified 
by conventional karyotype. Using CMA, delineation of the breakpoint of ring chromosome 21 
was possible in a case of RUNX1 haploinsufficiency. Further, inherited regions of homozygosity 
(ROH) were frequent in BMFS, and were located in the regions containing genes with autosomal 
recessive mutations, such as FANCA mutation in FA, DOCK8 mutations on chromosome 9 in 
primary combined immunodeficiency syndrome. Sequential CMA analysis in 25 patients at 
different time points including diagnosis, routine follow-up and relapse showed that 2 of 4 
relapsed patients had acquired CN-LOH. Hence, the authors suggested that repeating CMA at the 
time of suspected disease relapse had the highest yield. Interestingly, acquired CN-LOH was 
significantly more frequent in patients with acquired AA (aAA) than in the combined category of 
non-aAA BMFS patients (p<0.01). The most frequent acquired CN-LOH in aAA involved 6p. 
Other less common aberrations included 5q15qter, 6q12qter and 15q12qter, and these were 
mostly small clones [78].  
 
Some patients with familial platelet disorders with germline RUNX1 mutations have deletions 
encompassing multiple exons that cannot be detected by targeted NGS-based testing. In such 
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situations, CMA testing is one of the easiest methods of identification of such alterations, as 
illustrated in a patient in one study [80]. Further, CMA testing can help in detection of acquired 
secondary somatic alterations in these patients that often accompanies transformation to 
MDS/AML. In a study by Antony-Debre et al., 2 of 9 patients with familial platelet disorder with 
germline RUNX1 mutations  who transformed to AML had CN-LOH of chromosome 21 that was 
only detectable by CMA [81].  
 
Summary: A key question in the evaluation of BMFS patients is differential diagnosis of MDS or 
transformation to MDS/AML.  Literature evidence suggests that CMA is a valuable tool to 
address this question. Another differential diagnosis is AA or hypoplastic MDS. The presence of 
CN-LOH of 6p would suggest AA. 
 
d. Summary of the disease-based prognostic and therapeutic implications of CMA findings in 
precursor myeloid entities of ICUS, IDUS, CCUS, and CHIP    
CMA and targeted mutation profiling have identified MDS-associated alterations in the 
hematopoietic cells of normal individuals signifying that acquired somatic alterations were not 
restricted to patients with myeloid neoplasms [82-84]. Additionally, some patients with 
suspected MDS present with unexplained cytopenias and others present with dysplasia without 
cytopenias and fail to meet the standardized morphologic parameters of MDS.  Because these 
individuals do not meet the WHO diagnostic criteria for MDS or other hematological disease, 
provisional descriptive entities have been introduced into clinical practice to classify these 
diagnostically challenging patients. These entities include: a) patients with persistent peripheral 
blood unexplained cytopenias, normal bone marrow morphology, but no clonal karyotypic and 
MDS-associated mutations are classified as having idiopathic cytopenias of undetermined 
significance (ICUS); b) patients with a dysplastic bone marrow without cause, no or mild 
cytopenias and no clonal aberrations are classified as having idiopathic dysplasia of 
undetermined significance (IDUS); c) Clonal cytopenias of undetermined significance (CCUS) 
describes individuals with idiopathic cytopenias and clonal hematopoiesis (MDS-associated 
mutations and/or CMA-defined or non-MDS defining cytogenetic lesions), and d) clonal 
hematopoiesis of indeterminate potential (CHIP) has been proposed for patients with a clonal 
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alteration/mutation associated with hematologic neoplasia without cytopenias or dysplasia [82, 
85-88].   
 
Currently, little is known about the natural history of these preclinical entities but some degree of 
risk for either MDS or other hematologic malignancy is inferred. Molecular characterization of 
ICUS/IDUS cases using CMA and mutation profiling report a subset of these diagnostically 
ambiguous patients have acquired MDS-associated alterations (reported range, 35%-62%) [21, 
89, 90]. Allen et al. reported 5 of 12 IDUS/ICUS patients with normal cytogenetics showed 
clonal aberrations by array, indicating reclassification to CCUS. With a median of 28 months of 
follow-up, 3 of 3 CCUS patients reevaluated by subsequent bone marrow evaluation met the 
criteria for MDS or MDS/MPN within 6 months. Among the seven patients who did show clonal 
hematopoiesis, three ICUS patients subsequently met the criteria for MDS within 9 months. In a 
prospective study, Kwok et al. [89] studied 144 patients with unexplained cytopenias in which 
35% of ICUS patients carried a somatic mutation or chromosome aberration indicative of clonal 
hematopoiesis. In a different study designed to distinguish preclinical MDS from healthy 
individuals, Cargo and colleagues [90] reported 63 of 69 (91%) ICUS/CCUS patients showed 
either an array-based abnormality (23%) or a MDS-associated mutation in their non-diagnostic 
marrow.  The number of mutations and the variant allele fraction (VAF)/clonal size were notably 
greater in the ICUS patients vs. healthy individuals. For the 59 ICUS patient with a follow-up 
marrow sample, 39 patients eventually progressed to MDS or AML.   
 
The risk of progression for CCUS patients is unknown but suggested to be between CHIP and 
MDS. Because CHIP involves a mutated hematopoietic stem cell or immature progenitor cell, 
CHIP is currently viewed a precursor state for a broad range of hematopoietic neoplasms with a 
rate of progression to a hematologic neoplasm in the 0.5% to 1% per year, similar to the 
transition of monoclonal gammopathy of undetermined significance (MGUS) to multiple 
myeloma [88].  
 
Summary: The high frequency of CNAs/CN-LOH by CMA and somatic MDS-associated 
mutations recently reported in precursor myeloid entities provide potential objective markers of 
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disease. As these pre-malignant clinical entities evolve, molecular genetic testing is warranted 
for ambiguous morphology/diagnostically challenging patients.   
 
III. Important Pre-analytical and Post-analytical considerations for CMA and 
limitations of CMA testing 
 
a. Peripheral Blood vs. Bone Marrow  
For myeloid malignancies, studies have demonstrated a high level of concordance (95%) 
between CMA aberrations detected in peripheral blood (PB) and bone marrow (BM) [29]. Some 
authors have suggested that PB granulocytes may be a viable option for patients in which bone 
marrow/ karyotype analysis cannot be performed [61]. This is particularly helpful in elderly 
patients or in patients with fibrotic marrow and dry taps. Two studies have demonstrated that 
CNAs can be more readily identified in CD34+ cells compared to granulocytes or whole 
mononuclear cells [16, 61]. There is a significant correlation between gene aberrations detected 
in CD34+ cells of MDS patients by CMA with gene expression data [91]. However, isolating 
CD34+ cells is usually not feasible for routine clinical testing. Furthermore, in order to 
distinguish somatic from germline aberrations, it would be ideal to test BM samples with buccal 
DNA as matched germline control [16, 92, 93].  Again, this is not always feasible in a clinical 
laboratory.  Therefore, some laboratories may consider testing for remission samples instead.   
 
b. Formalin fixed paraffin embedded (FFPE) material  
FFPE tissue in the haematological setting offers an alternative tissue source when other more 
easily extracted tissue such as bone marrow aspirate samples are not available.  FFPE tissue is an 
excellent source of DNA, despite the detrimental effect that the fixatives used can have on the 
quality of the nucleic acids retrieved [94-97]. Many studies have demonstrated comparable 
performance between DNA obtained from FFPE samples and fresh frozen tissue, especially with 
modified protocols, and have shown concordance of CNVs obtained from FFPE and fresh frozen 
specimens [94, 98, 99].  CMA testing is reliable from FFPE specimens if optimised protocols are 
used [100, 101], ensuring minimum DNA quality, adequate input quantity and sufficient tumor 
burden.  Decalcified FFPE specimens are especially challenging. Nevertheless, Stevens-Kroef et 
al. demonstrated a high concordance between CMA on decalcified BM biopsy samples and 
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karyotyping on corresponding BM aspirates with a much higher resolution [102]. This is 
particularly valuable in obtaining clinically important genomic information in MDS cases with 
fibrosis and dry tap lacking cytogenetic data [102].   
 
IV. Limitations of CMA 
 
A variable number of aberrations were missed by CMA compared to karyotype or FISH, mostly 
due to low level clones, depending on the resolution of CMA testing and coverage [12, 26, 35, 
47, 61]. There are many commercial CMA platforms available and each should be independently 
validated in the laboratory to establish the limit of detection. The detection limit varies 
considerably in the studies reviewed as a consequence of biases and variability including disease 
selection, metaphase chromosome abnormality selection, differing CMA platforms, differing 
calling criteria and whether CMA analysis was performed blind to the metaphase chromosome 
analysis. In one study 142 cases of deletion 5q identified by metaphase chromosome analysis 
were identified by CMA analysis [33]. This contrasts to another study where 4/30 (13%) cases 
with CNAs of del(5q), del(7q), del(20q) and del(17p) by metaphase chromosome analysis with 
clonal levels of between ~10 to 15% remained undetected by CMA [28]. The detection limits of 
CMA and metaphase analysis are difficult to compare since karyotype by chromosome banding 
analysis evaluates only dividing cells while CMA analysis evaluates the entire cell pool.  
 
CMA analysis can only detect copy number changes and CN-LOH. Rearrangements that are 
genuinely balanced such as translocations and inversions, having no loss or gain of genetic 
material at the molecular level, cannot be detected using CMA technology, although one study 
estimated that 7% of abnormal CMA cases had an “unbalanced translocation” [42].  This implies 
that aberrations that appear balanced by metaphase chromosome analysis may be unbalanced by 
CMA technology due to sub-microscopic CNAs at one or more of the rearrangement 
breakpoints. Indeed, balanced rearrangements by karyotype have been shown to be unbalanced at 
the sub-microscopic level in 37% cases by CMA [103]. These imbalances may highlight the 
presence of a recurrent rearrangement, such as a CNV near the MECOM gene may represent a 
rearrangement of the MECOM gene. In this literature review, with the exception of CML, most 
studies reported either none or one case where a balanced rearrangement was missed; this 
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included one case of an inv(3)(q21q26) [104]. In MDS, other than inv(3) present in 1%, the 
common, recurrent chromosome abnormalities and prognostically significant abnormalities 
named in IPSS-R are copy number changes [4].  Therefore, CMA is ideal for MDS, MDS/MPN, 
and Ph-negative MPN. In general, if balanced rearrangements are also expected in the cancer 
type being studied, CMA should be supplemented by karyotype analysis and/or FISH [103]. 
Another limitation of CMA includes the inability to identify independent clones and the 
complexity of the sub-clones, i.e., clonal architecture that is obtainable by karyotype analysis. 
While clonal evolution can be deduced, this complexity may not be captured by CMA analysis 
alone [47, 105].  
 
Discussion  
The recent implementation of CMA into clinical laboratories has been an exciting and practical 
advancement in cytogenetic testing since the introduction of FISH technology as a new 
molecular cytogenetic tool in the 1990s. Despite the heterogeneity in study design, patient 
cohort, disease stage, CMA platform used, and criteria for aberration calls, the overall clinical 
diagnostic impact and advantages of CMA in MDS, MPN and MDS/MPN is evident.  The CMA 
technology has a considerably higher resolution for whole genome coverage; for example, a 
CMA platform with a functional resolution of 10-20 Kb has at least a 1000-fold increase in 
resolution when compared to karyotype analysis (5-10 Mb).  It also allows for more precise 
identification of genes involved in genomic abnormalities.  There is no requirement for dividing 
cells, and both fresh and formalin-fixed paraffin-embedded tissues could be used.  It showed 
equivalent diagnostic yield for MDS between blood and marrow, which is especially helpful.  
CMA is generally considered technically less laborious and more cost-effective than karyotype 
with great potential for multiplexing and automation. However, evidence for clinical utility is 
badly needed for routine utilization of this test by hemato-oncology providers and for better 
insurance coverage to benefit our patients. 
 
Key questions from providers typically include: (1) Are deletions and gains detected by CMA 
the same in terms of diagnosis and prognosis as those detected by karyotype and FISH?  (2) 
What does a finding of CN-LOH mean to my patient?  (3) How is CMA different from NGS 
testing?  Are they redundant? (4) Is CMA testing recommended by NCCN-guidelines? (5) Is 
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CMA paid by insurance companies?  (6) How do I use these new results?  We will highlight the 
answers to these questions as we summarize the evidence base below.  
  
Here, we present literature-based evidence on the application of CMA as a clinical diagnostic 
test in the work-up of MDS, MPN and MDS/MPN in specific clinical settings. We provide an 
example of a diagnostic testing algorithm for genomic testing in these neoplasms based on the 
complementary nature of CMA testing with current diagnostic modalities (Figure 1).  
 
Summary of Evidence Base: 
Table 1 summarizes the most important or unique CMA findings and their clinical utility in each 
disease entity while Tables 2-4 provides a comprehensive list of all the recurrent CMA findings 
reported in the literature based on our review. Diagnostic yield is generally high across the 
myeloid neoplasms (up to 80%) and is around 50% among those with normal or failed 
karyotype.  Even for patients with an abnormal karyotype, CMA can detect additional 
aberrations in approximately half of the cases.  The number of CMA abnormalities is usually 
low, with a median between 1 and 2.  Higher numbers are typically associated with advanced 
disease, disease progression, or high-risk disease. The concordance between FISH and CMA is 
excellent for CNAs, and the diagnostic and prognostic impact of the deletions and gains 
identified by CMA is equivalent to those by karyotype and FISH even in the setting of a clinical 
trial [12, 18, 21, 24, 106].  
 
In specific clinical scenarios, CMA testing offers advantages over routine karyotype as detailed 
below and summarized in Figure 1A. CMA is particularly useful in myeloid neoplasms with 
insufficient (<20 metaphases) or failed karyotype either due to the poor quality of the specimen 
or due to factors inherent to the disease condition such as bone marrow failure. In such 
situations, CMA testing of DNA extracted from residual cell pellets, aspirate smears or touch 
preps or FFPE sections is an alternative to karyotype and/or FISH.   
 
CN-LOH is prevalent in MDS/MPN and BCR-ABL1-negative MPN, with a reported frequency 
between 6%-41%. Currently, CMA is the only feasible technique available for identification of 
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CN-LOH. In addition to being a clonal marker, identification of CN-LOH can direct appropriate 
mutation analysis of specific genes of clinical significance.  
 
In the setting of normal karyotype, CMA provides additional information of clinical value. 
Additional aberrations detected by CMA over conventional karyotype are associated with worse 
survival in MDS patients [14, 26, 42, 43], MDS/MPN [12], and MPN [39] and also with disease 
progression to secondary leukemia or myelofibrosis [39, 55, 57, 59, 63, 107]. Additional CMA-
detected genomic aberrations and total genomic aberration measured by CMA can be used for 
further risk-stratification in both low and high IPSS/IPSS-R risk MDS patient groups [12, 14, 26, 
44]. Therefore, CMA can be helpful in low or intermediate-risk MDS patients, especially when 
straddling the prognostic range to more accurately assess the prognostic risk based on objective 
genetic data.  
 
CMA can detect potential markers of clonality in diagnostically challenging settings. These 
include cases with ambiguous morphology not diagnostic of a myeloid neoplasm, recently 
recognized as precursor myeloid entities, to differentiate BMFS from hypoplastic MDS, and 
assess progression of BMFS to MDS.  
 
Predictive markers remain scant even with the help of CMA. Specifically, response to 
lenalidomide among MDS patients with del(5q) and TKI resistance among CML patients did not 
correlate with CMA findings even though additional CNAs found by array and TP53 
mutations/17p deletions are associated with disease progression and worse prognosis [60, 62]. 
However, CMA is useful in detecting cryptic TET2 deletions and 4q CN-LOH. Recent evidence 
suggests that TET2 alterations could be a potential marker for response to demethylation agents, 
especially in the absence of ASXL1 mutation [68-70].   
 
Current Practice of CMA in Myeloid Neoplasms (expert opinion) 
Overall, CMA is extremely useful for work-up of patients with MDS, MDS/MPN, and Ph-
negative MPN along with karyotype, FISH and gene mutation analysis, where CNAs and CN-
LOH are the most common abnormalities in these diseases and balanced chromosomal 
abnormalities do not have a major role.  CMA provides a whole genome view at 1000x 
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resolution, from a gene to chromosome level in a single assay that does not require cell cultures. 
CMA facilitates detection of submicroscopic CNAs below the resolution of conventional 
karyotyping and adds precision with regards to breakpoint locations and the gene content. 
Accurate definition of breakpoints can suggest haploinsufficiency or disruption of a key gene 
and provide direction for appropriate mutation testing if clinically relevant. Most importantly, 
CMA is the only technique that allows detection of large CN-LOH, some of which are of 
prognostic value. This finding can also trigger mutational analysis of target genes of potentially 
predictive significance. In cases where karyotyping fails or cannot be performed, CMA allows 
detection of diagnostic and prognostic CNAs.  For MDS, there is a growing body of literature 
challenging the value of FISH following an adequate, normal karyotype analysis (He et al. 2016, 
Coleman et al. 2012, Jiang et al. 2011), prompting the recent Center for Medicare Services 
(CMS) proposal to eliminate coverage for MDS FISH when karyotype is successful. This further 
emphasizes the clinical utility of CMA in MDS. Limitations of CMA include inability to detect 
balanced rearrangements (noted in about 5% of the MDS patients), higher limit of detection than 
FISH, and reduced ability to fully resolve individual clones. 
 
Many clinical laboratories have implemented CMA for hematological malignancies.  The 
robustness of CMA offers great confidence in reporting new clonal findings which aid in 
diagnosis and prognosis.  With a resolution of 10-20 Kb, CMA cannot detect point mutations and 
indels except those at the SNP loci covered by the array design.  NGS is ideal to detect single 
nucleotide point mutations and small indels up to 1 Kb. NGS may also infer copy numbers but 
are not yet as accurately as CMA. Therefore, NGS and CMA can be utilized as complementary 
genomic testing tools. Mutation analysis, karyotype and FISH are recommended in practice 
guidelines available for myeloid neoplasms.  However, CMA has not been explicitly mentioned, 
which raises concerns among providers regarding the value of CMA.  
 
We present an example of an evidence-based testing algorithm to help promote the best clinical 
practice for diagnostic workup of MDS, MPN or MDS/MPN neoplasms by integrating CMA into 
current standard-of-care clinical laboratory testing tools (karyotype, FISH, morphology and 
flow) (Figure 1B). Many variations of this testing strategy can be applied based on local 
institutional standard of care. Initial evaluation typically includes karyotype analysis along with 
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morphology, and whenever possible, multiparameter flow cytometry immunophenotypic 
analysis.  NGS panel testing consisting of genes recommended by the NCCN guidelines is 
usually performed.  We suggest that CMA can be performed in specific scenarios of clinical 
significance: Anytime karyotype is unsuccessful, CMA is recommended. In MDS, if the 
karyotype is successful with an abnormal karyotype with a poor or very poor cytogenetics group 
classified per IPSS-R, no CMA testing is needed; patients are likely to receive aggressive or 
clinical trial regimens regardless of CMA findings. If the karyotype is successful with a very 
good, good or intermediate cytogenetics risk group, CMA is most helpful in patients with normal 
karyotype or in patients with cytogenetic risk-scores with uncertain IPSS/IPSS-R to accurately 
risk-stratify the patient.  Baseline FISH for the key stem clone abnormality based on the 
karyotype or CMA findings could be considered to identify an informative probe for future 
monitoring of minimal residual disease after therapy.   
 
Establishing a diagnosis of MDS may be challenging in the absence of diagnostic morphologic 
findings or a MDS-defining cytogenetic abnormality. In such patients, identification of CNAs, or 
CN-LOH in the regions of myeloid-related genes would trigger a more rigorous follow-up 
schedule in comparison to patients lacking these adverse prognostic markers. Our example MDS 
testing algorithm includes testing for ambiguous morphology/diagnostically challenging patients.  
Future large-scale prospective studies should assist in further refining the spectrum and number 
of specific mutations/chromosome aberrations involved in preclinical risk progression. 
 
For Ph-negative MPN, CMA may be helpful as a reflex to normal or failed karyotype while 
mutation testing appropriate for the specific subtype diseases should be carried out; for instance, 
JAK2 for PV and ET, CALR and MPL for myelofibrosis, and CSF3R for chronic neutrophilic 
leukemia. 
 
In CML, however, although higher numbers of chromosome abnormalities detected by CMA in 
addition to t(9;22) are clearly associated with blast crisis (76% vs. 58% in chronic phase), they 
have no predictive value for TKI resistance.  Therefore, CMA is not currently of high value in 
this scenario.  Quantitative real-time PCR is the preferred monitoring method; hence a baseline 
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Q-PCR for BCR/ABL1 is essential.  Occasionally, Q-PCR may be uninformative due to rare 
rearrangement breakpoints and FISH would be preferred for monitoring instead.   
 
The proposed algorithm may prove to be cost effective when CMA replaces extensive FISH 
panels routinely performed at diagnosis and that mutation testing could be by single- or 
multiplex-PCR or NGS depending on the availability at various clinical settings.   
 
Summary of cost/reimbursement information and published social economic consideration  
 
Payers, insurance companies and Medicare have their own policies based on research to 
determine reimbursement approvals and rates.  For example, Aetna considers CMA testing 
medically necessary for evaluating histologically equivocal Spitzoid melanocytic neoplasms 
(http://www.aetna.com/cpb/medical/data/700_799/0787.html). Furthermore, NCCN guideline on 
“Melanoma” (Version 3.2015) states to “Consider use of comparative genomic hybridization 
(CGH) or fluorescence in situ hybridization (FISH) for histologically equivocal lesions”.  The 
majority of such policy decisions is driven by consensus statements from professional societies 
or published clinical utility literature.  For example, an NGS cancer panel was approved by 
Palmetto (a contractor for the Centers for Medicare and Medicaid Services) for patients with 
advanced non-small cell lung cancer based on ASCO guidelines.  However, there have been no 
clear guidelines about when to use CMA testing in the context of hematological malignancies.  
Therefore, practicing laboratories have received widely varied rates of reimbursement for CMA. 
 
The Cancer Genomics Consortium (CGC) Working Group for Myeloid Neoplasms, in an 
international effort, has evaluated through a systematical peer-reviewed literature review, the 
clinical utility of CNA and CN-LOH evaluation by CMA in the non-AML myeloid neoplasms, 
and developed a working algorithm for optimal genome-wide testing by CMA. The data indicate 
such testing is appropriate in some scenarios for clinical management with equitable 
reimbursement similar to other molecular based testing is warranted in the light of this clinical 
utility information.   
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Future directions  
 
It is an exciting time when new technologies like CMA, NGS, exome sequencing, and whole 
genome sequencing are providing increasingly higher-resolution and cost-effective clinical test 
options for precision medicine. CMA is likely a cost-effective alternative to FISH panels (when 
karyotype is inadequate) for studies of copy number changes and allelic imbalances that provides 
more information. It is a whole-genome analysis approach unlike most of the current NGS panels 
that would only detect changes in the targeted regions. NGS is invaluable in mutation 
characterization, but the limitations of NGS panel based testing to detect CNVs in somatic/tumor 
samples and the advantages of using CMA for this purpose has been widely studied by various 
groups. Furthermore, CN-LOH analysis can be cumbersome with NGS panel testing [96, 97].  
Exome and whole-genome sequencing can help close the current gap of identifying genomic 
aberrations in the range between 1 Kb and 100 Kb in clinical use.  Eventually whole-genome 
sequencing or whole-exome sequencing will allow accurate assessment of CNAs and CN-LOH.  
Currently, CMA offers the best high-resolution tool for this application.   
 
This review clearly identified areas where we should further demonstrate the clinical utility of 
CMA. Precursor myeloid entities were only recently recognized.  Diagnosis based on genomic 
findings in the absence of morphological evidence remains to be established and require 
additional larger studies.  Many questions remain to be answered in myeloid disorders. Should 
CN-LOH be considered provisional evidence of a myeloid neoplasm as advocated by Gronseth 
et al [108]? What is the significance of CN-LOH in various chromosome arms?  How are they 
correlated with mutations or other structural aberrations important for diagnosis and prognosis?  
Last but not least, which of the recurrent findings may serve as predictive markers?  Clinical 
laboratories should join forces to address these questions by multicenter studies and clinical trials 
that include karyotype, FISH, NGS and CMA in order to establish the best genetic testing 
algorithm. One of the goals of CGC is to facilitate efforts in this direction by bringing multiple 
institutions and professional organizations under one umbrella.  
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Table 1. Evidence for the clinical utility of chromosomal microarray testing (CMA) in myeloid disorders excluding acute myeloid 
leukemia 
 
Disease 
Overall 
CMA 
detection 
rate 
Key and unique  
CMA aberrations 
Altered  
gene(s) 
Impact References 
MDS 
28-83% 
(Normal 
karyotype 
only: 11-
39%) 
Total genomic alteration  Prognostic poor survival  [26, 31, 35, 44, 48] 
  1p CN-LOH  Prognostic for progression to AML [14, 25, 36, 60, 104] 
  1q gain  Recurrent [14, 21, 30, 104] 
  4q loss TET2 Prognostic for poor survival [14, 21, 23, 24, 46] 
  4q CN-LOH TET2 Prognostic for poor survival [12, 14, 16, 21, 30, 35-37, 45, 63, 109] 
  5q loss  
5q loss “size” prognostic for 
progression to AML 
[14, 15, 21, 26, 33, 62, 104, 110] 
  7q loss CUX1, EZH2 Prognostic for poor survival 
[14, 15, 18, 30, 32, 38, 45, 60, 63, 78, 
102, 104, 107, 110] 
  7q CN-LOH  Recurrent  [12, 14, 21, 25, 30, 36, 48, 91, 109] 
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  11q CN-LOH CBL Prognostic/ recurrent [12, 14, 15, 25, 35, 36, 63, 104] 
  12p loss ETV6 Recurrent [14, 16, 30, 32, 46] 
  13q loss ?RB1 Recurrent [14, 21, 32, 35, 104] 
  17p loss TP53 Recurrent [14, 30, 34, 46, 102] 
  17p CN-LOH TP53 Diagnostic for advanced MDS/sAML [21, 30, 35, 36, 38] 
  20q loss  Recurrent [14, 60, 61, 64, 102, 107, 110] 
  21q CN-LOH or deletion RUNX1 Prognostic for progression to AML [14, 18, 32, 46, 60, 91] 
MDS/MPN 73%/NA 4q CN-LOH TET2 Recurrent [12, 20, 23, 63, 64] 
  7q CN-LOH Likely CUX1 Recurrent [12, 20, 36, 60, 63] 
  11q CN-LOH CBL Recurrent [12, 20, 23, 36, 43] 
MPN >56%/NA 1q gain   Recurrent [39, 54, 55] 
  4q loss TET2 Prognostic for progression to AML [24, 57] 
  9p CN-LOH JAK2 
Predictive for JAK2 inhibitors; 
Prognostic for PV progression to MF 
[39, 43, 54, 55, 111] 
  14q CN-LOH  
Presence of CNAs/CN-LOH prognostic 
for progression to AML 
[39, 54, 55, 60] 
  20q loss  Recurrent [39, 54, 112] 
CML 21-24%/NA 17p loss TP53 
Recurrent, progression, associated 
with TKI resistance 
[50, 51] 
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  2q CN-LOH  Diagnostic (only seen in BC) [51] 
  8p CN-LOH   Diagnostic (only seen in BC) [51] 
BMFS 19% (AA) 6p CN-LOH ?HLA genes Recurrent [77-79] 
  
*Recurrent indicates recurrent aberration with no established prognostic significance  
AA, Aplastic anemia  
BMFS, Bone Marrow Failure Syndrome  
MDS, Myelodysplastic Syndrome  
MDS/MPN, Myelodysplastic/ myeloproliferative Neoplasm  
MPN, Myeloproliferative Neoplasm  
CML, Chronic Myelogeneous Leukemia  
sAML, secondary AML  
TGA, Total genomic aberration  
TKI, tyrosine kinase inhibitors  
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Table 2.  A comprehensive list of CNAs and CN-LOH of known or likely clinical significance in MDS detected by CMA testing  
Chromosome Disease 
Abnormality 
Type (Gain, Loss, 
CN-LOH) 
Region 
Relevant Genes (if 
known) 
Clinical 
Significance* 
Level 
of 
Eviden
ce 
References 
1 MDS Gain 1p36.33-p33 MPL Recurrent 3 
 
[15] 
[14, 61] 
1 MDS CN-LOH 1p MPL Recurrent 2 
[14, 25, 36, 
60] 
1 MDS Gain 1q  Recurrent 2 
[14, 21, 30, 
104] 
2 MDS CN-LOH 2pter-2p13.3 DNMT3A Recurrent 2 
[14, 62, 63, 
113] 
3 MDS CN-LOH 3q21.3-qter MECOM, GATA2 Recurrent 3 
[14, 16, 19, 
35, 60] 
4 MDS Loss 4q24 TET2 T*** 2 
[14, 18, 21, 
23, 24, 32, 
46] 
4 MDS CN-LOH 4q12-qter TET2 Recurrent 2 
[12, 14, 16, 
21, 29, 30, 
36, 37, 45, 
63, 109] 
5 MDS Gain 5p 
Suggestive of i(5p) with 5q 
del 
Recurrent 3 [14] 
5 MDS Loss 5q RPS14 
D, P (Good when 
isolated) 
1 
[14-16, 18, 
19, 21, 26, 
30, 33-35, 38, 
42, 45, 48, 
61-64, 102, 
104, 110, 
114] 
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7 MDS Loss 7q EZH2, CUX1 
D, P 
(Intermediate) 
1 
[14, 15, 18, 
19, 26, 30, 
32, 34, 38, 
45, 48, 60, 
78, 102, 104, 
110] 
7 MDS CN-LOH 7q21.11-qter EZH2, CUX1 Recurrent 2 
[12, 14, 16, 
19, 21, 25, 
30, 36, 48, 
91, 109] 
7 MDS Loss (Monosomy) 7 Whole Chromosome D, P (Poor) 1 
[34, 38, 45, 
63, 78, 102, 
104, 107, 
110] 
8 MDS Gain (Trisomy) 8 Whole Chromosome 
P 
(Intermediate)** 
1 
[14, 21, 30, 
34, 46, 48, 
60, 61, 73, 
78, 102, 110] 
9 MDS Gain 9p JAK2 Recurrent 3 [14, 30, 46] 
9 MDS CN-LOH 9pter-p24.2 JAK2 Recurrent 2 [14, 31, 35] 
11 MDS Loss 11q14.1-q24.3 CBL D, P (Very Good) 1 [14, 61] 
11 MDS CN-LOH 11q13.3-qter CBL Recurrent 2 
[12, 14, 15, 
25, 35, 36, 
63, 104, 107] 
11 MDS 
Gain (Trisomy 
and q-arm) 
11 / 11q CBL Recurrent 3 
[14, 16, 26, 
30, 63] 
12 MDS Loss 12p ETV6 D, P (Good) 1 
[14, 16, 30, 
32, 46] 
12 MDS CN-LOH 12pter-p11.23 ETV6 Recurrent 2 [35, 63] 
13 MDS Loss 13q RB1 
D, P 
(Intermediate) 
2 
[14, 21, 35, 
104] 
13 MDS CN-LOH 13q12.3-qter FLT3, RB1 Recurrent 3 [14, 36, 63] 
13 MDS Gain (Trisomy) 13 Whole Chromosome Recurrent 3 [14] 
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14 MDS CN-LOH 14q24.2-qter CHGA Recurrent 3 
[14, 15, 25, 
29, 36] 
16 MDS 
Loss (Monosomy 
and q-arm) 
16 / 16q CDH1 Recurrent 3 [14, 46, 104] 
16 MDS CN-LOH 16q22.1-qter CDH1 Recurrent 3 [14, 91] 
17 MDS Loss 17p TP53 P (Poor) 1 
[14, 30, 34, 
42, 46, 48, 
102] 
17 MDS CN-LOH 17pter-p11.2 TP53 Recurrent 2 
[16, 21, 30, 
33, 35, 36, 
38, 48] 
17 MDS Loss 17q11.2 NF1 Recurrent 3 [32, 46] 
17 MDS CN-LOH 17q11.2-qter SRSF2, NF1 Recurrent 2 [14, 19, 25] 
19 MDS CN-LOH 19pter-p13.11 DNMT1, PRDX2 Recurrent 3 [60, 63] 
19 MDS Loss 19p13.13 PRDX2 Recurrent 3 [26] 
19 MDS Gain (Trisomy) 19 Whole Chromosome Recurrent 2 [14, 60] 
20 MDS Gain 20p 
Suggestive of ider(20p) 
with 20q del 
Recurrent 3 [14] 
20 MDS Loss 20q ASXL1 P (Good)** 1 
[14, 21, 26, 
42, 48, 60, 
61, 64, 91, 
102, 107, 
110] 
[15, 30, 45, 
112, 115] 
20 MDS CN-LOH 20q11.21-qter ASXL1 Recurrent 2 [48, 91] 
21 MDS Loss 21q22.12 RUNX1 D, P (Poor) 2 
[14, 16, 18, 
21, 32, 34, 
46] 
21 MDS CN-LOH 21q21.1-qter RUNX1, U2AF1 Recurrent 2 
[14, 25, 48, 
109, 114] 
21 MDS Gain (Trisomy) 21 Whole Chromosome Recurrent 2 [14, 30, 102] 
22 MDS CN-LOH 22q11.23-qter MN1, SF3A1, EP300 Recurrent 3 [14, 104] 
Downloaded for Anonymous User (n/a) at Indiana University - Ruth Lilly Medical Library from ClinicalKey.com by Elsevier on October 16, 2018.
For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved.
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
Legend: D- diagnostic significance; P-prognostic significance; T- therapeutic significance.  
Recurrent indicates recurrent aberration with no established prognostic significance.  
* Clinical significance based on WHO classification using IPSS-R (Greenberg et al., Blood  2012; Schanz et al., J Clin Oncol 2011).  
** Isolated trisomy 8 or del(20q) are not diagnostic of MDS in the absence of morphologic findings of disease.  
***Potential marker for responsiveness to hypomethylating agents or DNA methyltransferase inhibitors (Bejar et al., Blood 124:2705-
12, 2014;Traina et al., Leukemia 28:78-87, 2014). 
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Table 3.  A comprehensive list of CNAs and CN-LOH of known or likely clinical significance in MDS/MPN detected by CMA 
testing  
Chromosome Disease 
Abnormality Type 
(Gain, Loss, CN-LOH) Region Relevant Genes (if known) 
Clinical 
Significance* 
Level of 
Evidence References  
1 MDS/MPN CN-LOH 1p21.3  MPL Recurrent 2 [36] 
4 MDS/MPN Loss 4q24 TET2 Recurrent** 2 [23] 
4 MDS/MPN CN-LOH 4q12.4-qter  TET2 Recurrent 2 
[12, 20, 23, 
36, 63, 64] 
5 MDS/MPN 
Loss (Monosomy and 
q-arm) 5 / 5q RPS14 P (Intermediate) 1 
[23, 28, 33, 
43, 55, 62] 
7 MDS/MPN Loss 7q EZH2, CUX1 P (Poor) 1 [12, 43] 
7 MDS/MPN CN-LOH 7q21.11-qter EZH2, CUX1 Recurrent 2 
[12, 20, 36, 
60, 63] 
8 MDS/MPN Gain (Trisomy) 8 Whole chromosome P (Poor) 1 [55, 63]  
9 MDS/MPN CN-LOH 9pter-p13.3  JAK2 Recurrent 2 [36] 
11 MDS/MPN CN-LOH 11q13.2-qter  CBL Recurrent 2 
[12, 20, 23, 
36] 
12 MDS/MPN Loss 12p ETV6 P (Intermediate) 1 [20, 28] 
13 MDS/MPN Loss 13q RB1 P (Intermediate) 1 [43, 55] 
14 MDS/MPN CN-LOH 14q CHGA Recurrent 3 [36] 
17 MDS/MPN Loss 17p TP53 P (Poor)*** 1 [55] 
20 MDS/MPN Loss 20q ASXL1 P (Intermediate) 2 [43] 
21 MDS/MPN Gain 21q22.12 RUNX1 P (Intermediate) 2 [20, 23] 
21 MDS/MPN CN-LOH 21q22-qter  RUNX1 Recurrent 2 [20, 36] 
Legend: D- diagnostic significance; P-prognostic significance; T- therapeutic significance.  
Recurrent indicates recurrent aberration with no established significance.  
* Clinical significance based on International MDS/MPN Working Group recommendations [10]; No NCCN guidelines available. 
Low risk (normal, isolated –Y), Intermediate (others), High risk (+8, abnormal 7, complex). 
**Potential marker for responsiveness to hypomethylating agents or DNA methyltransferase inhibitors [68, 71] 
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***Haploinsufficiency of 17p as part of an isolated isochromosome may be a distinct disease entity with further increased risk of 
AML progression relative to 17p loss in a complex karyotype.
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Table 4. A comprehensive list of CNAs and CN-LOH of known or likely clinical significance in  
MPN detected by CMA testing 
 
Legend: D- diagnostic significance; P-prognostic significance; T- therapeutic significance.  
Recurrent indicates recurrent aberration with no established significance.  
* Clinical significance based on NCCN guidelines [5]; For myelofibrosis, unfavorable [complex 
karyotype or sole or two abnormalities that include inv(3), 5/5q-, 7/7q-, +8, 11q23 
rearrangement, 12p-, and (17q)]  
  
Chromoso
me 
Diseas
e 
Abnormali
ty Type 
(Gain, 
Loss, CN-
LOH) Region 
Relevant Genes 
(if known) 
Clinical 
Significanc
e* 
Level of 
Evidenc
e 
Referen
ce 
(PMID) 
1 MPN CN-LOH 1p21.3 MPL Recurrent 2 [39] 
1 MPN Gain 
1q21.2-
q32.1    Recurrent 2 
[39, 54, 
55] 
4 MPN Loss 4q24 TET2 Recurrent 2 [24, 57] 
5 MPN Loss 5q RPS14 P (Poor) 1 [62] 
6 MPN Loss 6p23-22.3 JARID2 Recurrent 3 [55, 59] 
7 MPN Loss 7q EZH2, CUX1 P (Poor) 1 [39] 
7 MPN CN-LOH 7q22.1-qter  EZH2, CUX1 Recurrent 2 [51] 
8 MPN 
Gain 
(Trisomy) 8 
Whole 
chromosome P (Poor) 1 [50] 
9 MPN Gain 9p JAK2 Recurrent 2 
[39, 54, 
55] 
9 MPN CN-LOH 9pter-p13.3 JAK2 Recurrent 2 
[39, 43] 
[54] [55, 
111] 
9 CML Loss 9q34   Recurrent 3 [49, 50] 
9 CML Gain 9q34 (+Ph) ABL1 Recurrent 1 [50] 
11 MPN CN-LOH 11q13.4-q25   CBL Recurrent 2 [39, 54] 
12 MPN Loss 
12p13.3-
p12.2 ETV6 P (Poor) 1 [51] 
13 MPN Loss 13q RB1 Recurrent 1 [54] 
14 MPN CN-LOH 14q CHGA Recurrent 3 
[39, 54, 
55, 60] 
17 MPN Loss 17p TP53 P (Poor) 1 
[50, 51, 
54] 
20 MPN Loss 20q ASXL1 Recurrent 1 
[39, 54, 
112] 
22 CML Loss 22q11.2   Recurrent 3 [49, 50] 
22 CML Gain 
22q11.2 
(+Ph) BCR Recurrent 1 [50] 
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Figure Legends  
 
Figure 1. (A) Clinical Scenarios where detection of CNA and CN-LOH is of additional value to 
current standard of care testing modalities. (B) An example testing algorithm for MDS, 
MDS/MPN and MPN in a clinical laboratory.  Every patient with a suspected diagnosis of MDS 
or MPN should have karyotype analysis performed at diagnosis, along with morphology 
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evaluation, flow cytometry analysis and mutation analysis (if considered appropriate and 
feasible).  In the case of CML with t(9;22) by karyotype, quantitative real-time PCR is the 
preferred monitoring test.  For patients with suspected MDS, MDS/MPN or Ph-negative MPN 
diagnoses, chromosomal microarray testing (CMA) is recommended if the karyotype is 
unsuccessful; for MDS patients with successful karyotype showing very good, good or 
intermediate cytogenetic risk-groups per IPSS-R stratification, CMA is especially helpful in 
patients with normal karyotype and in patients with uncertain IPSS/IPSS-R risk score to further 
assist with diagnostic uncertainty and risk stratification**.  In MDS patients when del(5q) is 
detected by karyotype as a sole abnormality or along with one additional abnormality other than 
del(7q)/-7, 2016 WHO classification system recommends performing TP53 mutation studies for 
identifying those patients with poor response to lenalidomide. The genes in the mutation analysis 
panel should be based on the NCCN guideline and may be tailored to the needs and technology 
available at each institution.  SF3B1, ASXL1, RUNX1, EZH2, ETV6 and TP53 for MDS and 
JAK2, CALR, MPL, TET2 for MPN are typical examples. If feasible, when clonal copy number 
alterations (CNAs) are identified by either CMA or karyotype, a baseline FISH for the key stem 
clone could be considered to establish an informative FISH marker for future monitoring of 
minimal residual disease post-treatment. In patients with ambiguous morphology, CMA is 
helpful for identification of clonal markers.  
* Cytogenetic risk-groups classified per IPSS-R [2, 4]  
** At this time, IPSS-R is based on karyotype assessed by chromosome banding analysis only. 
Further multi-center studies to comprehensively evaluate the prognostic impact of additional 
findings by genomic arrays compared to IPSS-R need to be undertaken.  
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